DNMT3B and breast carcinoma: Currently, there is no specific research on DNMT3B in glioma, but DNMT3B has been reported to accelerate the occurrence and progression of esophageal cancer (38), lung cancer (39), breast cancer (40), and ovarian cancer (41), implying that DNMT3B is an essential biomarker in cancer pathogenesis.